Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

What are Moderna investors actually betting on?

Anonymous
Conditions
July 24, 2020
272 Shares
Share
Tweet
Share

Moderna’s stock price has continued to climb to record highs on the premise that their novel mRNA-based vaccine technology can take control of the spread of COVID-19. Since the beginning of January 2020 to the time of the writing of this article, the stock has increased by an astronomical 385 percent, based on preclinical and phase I data alone. Moderna, a vaccine-biotech company with no vaccines on the market, is currently valued around $37 billion dollars, which is equivalent to over half the amount of the $54 billion in revenue brought in by global vaccine sales in 2019. Clearly, those buying stock in Moderna believe that their vaccine could end the pandemic. As innovative as Moderna’s mRNA-vaccine platform poses to be, one of the biggest questions that no one is asking is whether Moderna’s COVID-19 vaccine is actually a good financial investment from the investor’s perspective?

Moderna is on track to commercialize a pioneering COVID-19 vaccine utilizing novel mRNA-vaccine technology to trigger immunity in patients. This will be the first of its kind if the FDA approves it as there are no approved mRNA vaccines on the market. The latest phase I data published in the New England Journal of Medicine earlier this month demonstrated the safety of the vaccine as well as showing the induction of neutralizing antibodies in a group of 45 patients.  These antibodies were shown to prevent the coronavirus from entering human cells in vitro (in a laboratory setting). Although this is hopeful and encouraging data, the justification of the soaring stock of Moderna seems premature at best. For any new vaccine, the true efficacy can only be determined by a large randomized control phase III trial where the vaccine efficacy is defined as the percent reduction in the incidence of disease among the vaccinated compared to the incidence of the non-vaccinated. Until that data is released, the investor has no way of knowing if the Moderna’s COVID-19 vaccine or its mRNA platform definitely works.

Another challenge investors face is determining if Moderna’s COVID-19 vaccine is going to be a one-hit-wonder or whether it will continue to be needed in the years-to-come. The best-case scenario for Moderna is that COVID-19 becomes a seasonal upper respiratory infection like the flu, and the vaccine has to be administered every year, providing a continuous source of revenue for Moderna. On the other hand, the worst-case scenario for Moderna is that the vaccine works extremely effectively and provides long term immunity against COVID-19 making administering the vaccine every year obsolete. Blockbuster drugs like Lipitor and Humara are big money makers and great investments because patients continuously need to take the drug. It is still too early to determine if Moderna’s COVID-19 vaccine will be needed beyond 2020-2021.

Lastly, a big unknown for investors is how Moderna will choose to price their product. Gilead is treading carefully in its pricing of Remdesivir, an anti-viral that shortens hospital stays for COVID-19 patients by three to four days. Gilead’s chief executive Daniel O’Day has made clear that Remdesivir “is priced far below the value it brings to the health-care system.” Gilead is not charging the maximal price for the drug due to fear of public scrutiny in light of the global pandemic. Moderna faces a similar issue and may not charge the true market value for the vaccine to avoid accusations of price-gouging during a pandemic. However, unlike Gilead, Moderna currently does not sell any products. Moderna’s market debut will be the COVID-19 vaccine, and they could potentially be selling their first source of revenue at a discount.

In the case of Moderna, investors should at least raise an eyebrow at its soaring stock price. There are still many unanswered questions, and only time will provide clarity. I would feel a lot better investing in Moderna knowing the efficacy of the vaccine, knowing the vaccine will be used in perpetuity similarly to the HPV vaccine, and know Moderna will price the vaccine in a way to ensure I receive a return on my investment. A good investment should promise the safety of the principle as well as provide a reasonable return of investment. At this time, an investment in Moderna can do neither.

The author is an anonymous medical student.

Image credit: Shutterstock.com

Prev

As an oncologist, this is the hardest role I play

July 24, 2020 Kevin 0
…
Next

Stop honoring health care workers with sugary treats

July 24, 2020 Kevin 2
…

Tagged as: COVID, Infectious Disease

Post navigation

< Previous Post
As an oncologist, this is the hardest role I play
Next Post >
Stop honoring health care workers with sugary treats

More by Anonymous

  • Navigating the broken medical system: challenges faced by foreign medical graduates

    Anonymous
  • In the trenches of health care: Facing unbearable strain

    Anonymous
  • Iranian doctors’ bravery: Upholding medical ethics amidst oppression

    Anonymous

Related Posts

  • People over profit: Pfizer and Moderna must share vaccine technology

    Amber Gipson-Fine, MPH
  • The COVID vaccine selfie: The caption matters as much as the picture

    Alicia Billington, MD, PhD
  • Where’s the big COVID data?

    Anuradha Kolluru, MD and Rakesh Lattupalli, MD
  • Major medical groups back mandatory COVID vaccine for health care workers

    Molly Walker
  • Is it time for a true federal COVID vaccine mandate?

    Shetal Shah, MD
  • COVID-19 divides and conquers

    Michele Luckenbaugh

More in Conditions

  • Debating the role of psychiatric assessments in medical decisions

    Christian Youssef & Francisco M. Torres, MD
  • 5 things to know about weight from a bariatric surgeon

    Maria Iliakova, MD
  • Physician autonomy and patient interactions in corporate health care

    Michele Luckenbaugh
  • Vague criteria can lead to misdiagnosis and prison

    L. Joseph Parker, MD
  • U.S. maternal mortality crisis: a deep dive

    Alan Lindemann, MD
  • Contemporary weight loss: Unveiling the quest for elusive elixir

    Osmund Agbo, MD
  • Most Popular

  • Past Week

    • Reigniting after burnout: 3 physician stories

      Kim Downey, PT | Physician
    • I’m a doctor, and I almost died during childbirth

      Bayo Curry-Winchell, MD | Physician
    • I’m tired of being a distracted doctor

      Shiv Rao, MD | Tech
    • Inside the grueling life of a surgery intern

      Randall S. Fong, MD | Physician
    • Debating the role of psychiatric assessments in medical decisions

      Christian Youssef & Francisco M. Torres, MD | Conditions
    • Balancing motherhood and medicine [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Medical gaslighting: a growing challenge in today’s medical landscape

      Tami Burdick | Conditions
    • I want to be a doctor who can provide care for women: What states must I rule out for my medical education?

      Nandini Erodula | Education
    • Balancing opioid medication in chronic pain

      L. Joseph Parker, MD | Conditions
    • Mourning the silent epidemic: the physician suicide crisis and suggestions for change

      Amna Shabbir, MD | Physician
    • Reigniting after burnout: 3 physician stories

      Kim Downey, PT | Physician
    • Misunderstandings about opioid use disorder

      Amy Baxter, MD | Conditions
  • Recent Posts

    • Debating the role of psychiatric assessments in medical decisions

      Christian Youssef & Francisco M. Torres, MD | Conditions
    • Navigating adulthood in the digital age

      Eleanor Menzin, MD | Physician
    • 5 things to know about weight from a bariatric surgeon

      Maria Iliakova, MD | Conditions
    • Out-of-office infusions in oncology care [PODCAST]

      The Podcast by KevinMD | Podcast
    • The power of business knowledge for medical professionals

      Curtis G. Graham, MD | Physician
    • Using the language of art to create work-life balance

      Sarah Samaan, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • New Schizophrenia Treatments Are Coming: Don't Panic
  • Heavy Drinking Not Tied to Lower Response to DAAs for Hepatitis C
  • Higher Suicide Risk in Nurses, Other Health Workers
  • COVID Drug and New Mutations; Costco Offers $29 Care; Trump Unmasked Over Bronzer
  • Long COVID Rare in U.S. Kids, Has Affected 7% of Adults

Meeting Coverage

  • New Schizophrenia Treatments Are Coming: Don't Panic
  • Loneliness Needs to Be Treated Like Any Other Health Condition, Researcher Suggests
  • Stopping Medical Misinformation Requires Early Detection
  • AI Has an Image Problem in Healthcare, Expert Says
  • Want Better Health Outcomes? Check Out What Other Countries Do
  • Most Popular

  • Past Week

    • Reigniting after burnout: 3 physician stories

      Kim Downey, PT | Physician
    • I’m a doctor, and I almost died during childbirth

      Bayo Curry-Winchell, MD | Physician
    • I’m tired of being a distracted doctor

      Shiv Rao, MD | Tech
    • Inside the grueling life of a surgery intern

      Randall S. Fong, MD | Physician
    • Debating the role of psychiatric assessments in medical decisions

      Christian Youssef & Francisco M. Torres, MD | Conditions
    • Balancing motherhood and medicine [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Medical gaslighting: a growing challenge in today’s medical landscape

      Tami Burdick | Conditions
    • I want to be a doctor who can provide care for women: What states must I rule out for my medical education?

      Nandini Erodula | Education
    • Balancing opioid medication in chronic pain

      L. Joseph Parker, MD | Conditions
    • Mourning the silent epidemic: the physician suicide crisis and suggestions for change

      Amna Shabbir, MD | Physician
    • Reigniting after burnout: 3 physician stories

      Kim Downey, PT | Physician
    • Misunderstandings about opioid use disorder

      Amy Baxter, MD | Conditions
  • Recent Posts

    • Debating the role of psychiatric assessments in medical decisions

      Christian Youssef & Francisco M. Torres, MD | Conditions
    • Navigating adulthood in the digital age

      Eleanor Menzin, MD | Physician
    • 5 things to know about weight from a bariatric surgeon

      Maria Iliakova, MD | Conditions
    • Out-of-office infusions in oncology care [PODCAST]

      The Podcast by KevinMD | Podcast
    • The power of business knowledge for medical professionals

      Curtis G. Graham, MD | Physician
    • Using the language of art to create work-life balance

      Sarah Samaan, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...